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Background/aim: Chronic constipation (CC) and celiac disease (CD) are the most common conditions encountered in pediatric
gastroenterology. The association of these two disorders has not been evaluated properly. We analyzed the prevalence and outcome of
CD in children with CC.
Materials and methods: The study included children with CC (n = 313) and healthy children (n = 990). Serum IgA and IgA antitissue
transglutaminase antibodies (IgA-tTG) were studied in all subjects. Intestinal biopsy and HLA-DQ2/DQ8 typing was performed in
subjects with elevated IgA-tTG.
Results: Serology was positive in 8 children (2.5%) with CC and 6 children (0.6%) from the control group (P < 0.05). Histopathological
examination revealed total villous atrophy in two subjects in the control group. Other subjects had Marsh 0–1 lesions. All patients with
CC and 4 children from the control group were classified as having potential CD. Two children in the control group had silent CD.
Spontaneous loss of serum tTG-IgA occured in 75% of the subjects with potential CD at the end of the 1st year.
Conclusion: Our study revealed that serological evaluation CD may be omitted in children with CC at initial examination. It may be
perform in selected patients such as those associated with prolonged symptoms or malnutrition.
Key words: Chronic constipation, celiac disease, potential

1. Introduction
Celiac disease (CD) is an immune-mediated systemic
disorder triggered by gluten-containing grains in
genetically suspected individuals. It is one of the most
common lifelong disorders and affects approximately
1% of the general population (1–3). It is characterized
by a wide range of clinical presentations, ranging from
typical malabsorptive symptoms including chronic
diarrhea, abdominal distention, and failure to thrive, to
extraintestinal manifestations such as osteopenia, isolated
short stature, and elevated liver enzymes (1,2).
Chronic constipation (CC) is one of the most common
conditions encountered in general pediatric and pediatric
gastroenterology offices (4). It is defined as decrease
in defecation frequency or painful defecation, and is
sometimes associated with involuntary loss of stool. It
is mainly functional and there is no identifiable organic
lesion or disorder in most cases. Most of the cases respond
to toilet training, diet, and medical treatment. However, a
minority of children with CC does not respond to medical
* Correspondence: muratcak@hotmail.com

treatment and may present an inextricable condition for the
physician and parents (5). Although it is not recommended
to perform routine screening tests for organic causes such
as CD, hypercalcemia, and hypothyroidism in the absence
of alarm symptoms according to a recent guideline by
ESPGHAN and NASPGHAN, most physicians perform
these tests in order to rule out organic causes at initial
admission (5).
Peptide YY is a novel neuroendocrine peptide that
localizes endocrine cells in the colon. It plays an important
role in regulating gastrointestinal motility and absorption
of water and electrolytes. Increased levels of peptide YY
were shown in children with slow transit constipation
(6,7). Elevated levels of peptide YY were also reported
in patients with newly diagnosed CD (7). Therefore, the
coexistence of CD and CC may be seen more commonly
and patients with CD may present with CC. However,
the prevalence of CD in children admitted only with
the compliant of CC has not been properly evaluated
previously. Therefore, we aimed to analyze the prevalence
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of CD in children admitted with CC and the outcome of
these patients.
2. Materials and methods
The study included children (>1 and <17 years old) who were
admitted to the pediatric gastroenterology unit with the
complaint of CC during a 1-year period (n = 360). Patients
with definite organic problems (n = 40, 11.1%) such as
spinal cord problems and intestinal pseudoobstruction (n
= 16), drug- or toxin-related problems (n = 10), anatomic
problems (n = 5), endocrinological problem (n = 4), Down
syndrome (n = 2), Hirschsprung disease (n = 2), and pelvic
mass (n = 1), and patients with previous diagnosis of CD
(n = 4, 1.1%) and family history of CD (n = 3, 0.8%) were
excluded from the study. Demographic features, clinical
findings, accompanying symptoms, and anthropometric
measurements of the patients were recorded (n = 313,
86.9%). All the children fulfilled the Rome III criteria at
the time of initial examination (8,9). The control group
included healthy children without known chronic diseases
and CC (> 1 and < 17 years old). The number of children
in the control group was calculated according to previous
population studies on CD prevalence in Turkey. With the
assumption that CD is expected to occur in 1% of the
population, we calculated that a sample of 1510 healthy
children has 95% confidence interval, but due to limited
financial resources 1000 healthy children were included
to the study. Due to a technical problem (inadequate
material), 10 children were excluded during the laboratory
examinations (n = 990).
Between 5 and 10 mL of peripheral venous serum
samples were obtained from all patients with CC and all
children in the control group in order to study serum
IgA and IgA antitissue transglutaminase antibodies
(IgA-tTG). IgA levels were measured on a Dade Behring
nephelometer using Dade Behring reagents. Patients with
IgA deficiency according to their age were further tested
for IgG-tTG. Antibodies against human IgA and IgG-tTG
were tested with an enzyme-linked immunosorbent assay
(Euroimmune, GmbH) kit. The cutoff level for IgA and
IgG-tTG defining a positive result was set at 20 RU/mL (the
maximum calibrator was 200 RU/mL). All sera positive
for IgA-tTG and IgG-tTG were further tested for IgA
antiendomysial antibodies (IgA-EMAs) using an indirect
immunofluorescence method. The EMA determination
was conducted with a commercial kit (EUROPLUS
Primate Liver and Gliadin (GAF - 3X) BIOCHIPs, GmbH)
following the manufacturer’s instructions. Sera were
considered positive in a 1:10 dilution. Additionally, all
sera positive for IgA-tTG or IgG-tTG were further tested
for HLA-DQ2 and HLA-DQ8 typing. Genomic DNA of
subjects in the study were isolated from 200 mL aliquots
of peripheral venous blood samples by using the Bio-
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robot EZ1 magnetic bead-based workstation (Qiagen).
Genotyping of HLA-DQ2 and HLA-DQ8 alleles were
performed in all subjects by polymerase chain reaction
with sequence specific oligonucleotide probes (PCRSSOP) hybridization method using Luminex technology
(Gen-probe Lifecodes).
A small-intestinal biopsy was offered to all subjects
with IgA and IgG-tTG positivity. Three biopsy specimens
were taken from the bulbus and the second part of the
duodenum and carefully oriented on filter paper before
submersion in 10% neutral buffered formalin. The biopsies
were evaluated by the same expert histopathologist. The
Marsh classification was used for the histopathological
classification. Normal mucosa with >30 intraepithelial
lymphocytes per 100 epithelial cells was defined as Marsh
type 1, infiltrative/hyperplastic lesions were defined as
Marsh type 2, and villous atrophy was defined as type 3
(10).
Patients with positive serology were classified as:
1) overt CD (silent or symptomatic): positive serology
together with the features of mucosal changes on intestinal
biopsy (Marsh stage 2–3) (these patients were initiated
on a strict gluten-free diet); and 2) potential CD: positive
serology with normal or slightly infiltrated bowel mucosa
(Marsh stage 0–1) (patients with potential CD were
suggested to continue their unrestricted gluten-containing
diet). After diagnosis, serology and clinical symptoms
were determined with 6-month intervals for 1 year.
Informed consent for participating in the study was
obtained from the parents of all participants and the ethics
committee of the Karadeniz Technical University Faculty
of Medicine approved this study.
Data were analyzed using SPSS 16.0. Differences
between groups were calculated using an independent
samples t-test for the normally distributed data and the
Mann–Whitney test for data not normally distributed.
Chi-square test was used for the comparisons of qualitative
data. Values of P < 0.05 were considered significant.
3. Results
Demographic and clinical features of the patient and
control groups are shown in Table 1. There was no
significant difference between the groups in terms of sex
(female sex: 56.2% vs. 51.3%, P > 0.05) and age (5.8 ± 3.7
vs. 5.1 ± 2.6 years of age, P > 0.05). Underweight (weight
for age) and obesity were more common in children with
CC (12.1% vs. 7.5%, P < 0.05, and 10.2% vs. 2.4%, P < 0.05,
respectively).
Duration of constipation (mean ± SD) was 2.6 ± 1.1
years and 103 patients (32.9%) had family history of CC.
Clinical features of the patients with CC are shown in
Table 2. The most common symptoms were painful or
hard bowel symptoms (96.4%), followed by ≤2 defecations

ÇAKIR et al. / Turk J Med Sci
Table 1. Demographic characteristics of the patients with CC and the healthy controls.
Patients with CC (n = 313)

Healthy children (n = 990)

Sex: female, n (%)

176 (56.2)

508 (51.3)

Age; mean ± SD, years

5.8 ± 3.7

5.1 ± 2.6

>1– ≤5 years

134 (42.8)

591 (59.7)

>5– ≤10 years

127 (40.5)

347 (35.1)

>10 years

52 (16.7)

52 (5.2)

Underweight, n (%)

38 (12.1)

75 (7.5)

Obesity, n (%)

32 (10.2)

24 (2.4)

Age group; n (%)

Table 2. Clinical findings of the patients with CC (n = 313).
Parameters

Number of cases (%)

Rome III diagnostic criteria
≤2 defecations per week

202 (67.7)

Fecal incontinence

67 (21.4)

Retentive posturing

199 (63.5)

Painful or hard bowel movements

302 (96.4)

Large fecal mass in the rectum

188 (60)

Large-diameter stools

35 (11.1)

Accompanying symptoms
Rectal bleeding

113 (36.1)

Vomiting

50 (15.9)

Abdominal pain

224 (71.5)

Decreased appetite

24 (7.6)

Ribbon-like stools

274 (87.5)

Urinary tract infection

57 (18.2)

per week (67.7%). Ribbon-like stools and abdominal pain
were seen in 87.5% and 71.5% of the patients, respectively.
Serology positivity (tTG-IgA>20 RU/ml ) was found
in 8 children (2.5%, 95% CI: 0.77–4.23) with CC and in
6 children (0.6%, 95% CI: 0.12–1.08) from the control
group (P < 0.05, OR: 4.3, 95% CI: 1.48–12.4). tTG-IgA
levels were <100 RU/mL in all children with CC. In the
control group, tTG-IgA levels were >200 RU/mL in two
children and <100 RU/mL in the others. IgA deficiency
was found in 4 children (1.2%) with CC and in 7 children
(0.7%) from the control group, and none had tTG-IgG

positivity. Endoscopy was performed in all subjects with
positive serology (n = 14). Histopathological examination
revealed total villous atrophy (Marsh 3) in two subjects
who had tTG-IgA > 200 RU/mL in the control group.
Other subjects had Marsh 0–1 lesions. At the end of the
serologic and histopathological examinations all patients
with CC (8/313, 2.5%) and 4 children (4/990, 0.4%) from
the control group were classified as having potential
CD. Two children in the control group had silent CD
(2/990, 0.2%) (Figure 1). Demographic, laboratory, and
histopathological findings of the subjects with positive
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Patients with CC were followed with gluten containing
diet. tTG-IgA levels were negative in 5 of the 8 patients in
the 6th month. tTG-IgA levels increased in one patient,
and decreased in 2 patients, but remained above the 20 RU/
mL. Only one patient with increased tTG-IgA levels had
constipation despite medical treatment at the 6th month.
In the 1st year tTG-IgA levels became negative in one
patient (a total of 6 patients were negative in the 1st year).
One patient had decreased tTG-IgA levels, but the value
remained above 20 RU/mL (case 7 in the patient group) .
tTG-IgA levels continued to increase in the last patient who
had increased tTG-IgA levels in the 6th month. The patient
had unresponsive constipation and second endoscopy
was performed. Histopathological examination revealed
Marsh 1 lesion, and he was started on gluten-free diet due
to positive serology and intractable constipation (case 5 in
the patient group). The subjects in the healthy group with
silent CD were initiated on strict gluten-free diet. tTG-IgA
levels decreased in the 6th month and became negative in
the 1st year in these subjects. tTG-IgA levels increased in
2 of the other 4 subjects in the 6th month, but they did
not have gluten-related symptoms. The other two subjects
became negative in the 6th month. Only 1 subject had
elavated tTG-IgA levels (98 RU/mL) in the 1st year, but the

5
P < 0.05, OR: 4.3

% of positive serology

4.5
4
3.5
3
2.5
2

2.5 %

1.5
1
0.5
0

0.2 %

0.4 %
Patients with CC (n=311)

Healthy children (n=990)

Figure 1. Prevalence of CD in children with CC and healthy
children. Note that the prevalence of potential CD is more
common in children with CC than in the healthy children (white
boxes indicate potential CD and black boxes indicate silent CD;
black lines indicated 95% confidence interval).

serology are shown in Table 3. Of the 8 patients with
positive serology in CC group, 5 (62.5%) had constipation
over 3 years, and 3 children had malnutrition (37.5% in
serology positive vs. 11.4% in serology negative, P = 0.02).

Table 3. Clinical and laboratory findings of the subjects with positive serology.
Age*/S

W/Hp

DC
(year)

Ferritine&
(ng/mL)

tTG-IgA
(RU/mL)

HLA
DQ2/DQ8

EMA

Marsh FD

Patients with CC
Case 1

3/M

50–75/50–75

1

28.7

37

+/–

–

0

P

Case 2

2/F

<3/<3

1

34.1

28.5

+/–

–

0

P

Case 3

7.5/F

75–90/50–75

7

64.2

43.3

+/–

+

0

P

Case 4

3.5/M

10/25

3

26

78.8

–/+

–

1

P

Case 5

11/M

50–75/50–75

10

14.4

77.3

+/–

++

1

P

Case 6

4/F

<3/<3

3

36.4

50.9

–/+

–

1

P

Case 7

3.5/F

50–75/75

1.5

21.9

62

+/+

–

1

P

Case 8

9/M

<3/3–10

8

20

93

–/–

+

1

P

Case 1

4/F

50–75/3–10

-

29.3

25.3

+/–

–

1

P

Case 2

1.5/F

50–75/50–75

-

78

78.4

+/–

+

1

P

Case 3

2.5/F

10/10–25

-

8.6

>200

+/–

+++

3

S

Case 4

2/F

50–75/50

-

20

>200

+/–

+++

3

S

Case 5

2/M

90–97/90–97

-

93

87

+/–

+

1

P

Case 6

2/F

25–50/25–50

-

57

58

+/–

–

1

P

Control group

*: age in years, DC: duration of constipation, FD: final diagnosis, S: sex, W/Hp: weight/height percentile, P: potential CD, S: silent CD,
&
: normal values > 12 ng/mL.
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parents did not consent to endoscopy (case 2 in the control
group) (Figure 2). Overall, spontanous loss of serum tTGIgA occured in 9 of the 12 (75%) subjects (patients with
CC and healthy children).
4. Discussion
In this study we analyzed the association between CC
and CD. Motility problems such as increased frequency
of gastroesophageal reflux disease, prolonged gastric
emptying, decreased postprandial antral motility, and
prolonged orocecal transit time have been reported in
patients with active CD (11–13). The association of CC with
CD was first reported by Egan-Mitchell and McNicholl in
1972 (14). They reported that 12 of 112 infants or children
(10.7%) had constipation before the diagnosis of CD.
They suggested that constipation is related with decreased
intestinal motility due to mucosal inflammation. In a recent
report from Turkey, CC was found in 6.8% of patients at
the time of initial admission (15). However, reports about
the frequency of CD in patients admitted with CC are
rare. Pelleboer et al. (16) studied the prevalence of CD in
patients with CC, referred by their general practitioner to
a pediatrician because of failure of laxative treatment, and
they found increased prevalence of CD in these children
(7 in 370 patients, 1.9%); they recommend screening for
CD in patients with CC who do not respond to medical
treatment. On the other hand, Chogle and Saps (17)
analyzed the prevalence of CD in patients with CC (n =
1731) and they found similar prevalence of CD in children
with CC (n = 33, 1.9%) and in the healthy population
(only 3 patients had the sole symptom of constipation as
a presenting symptom); they do not recommend routine
screening for CD in patients with CC. Similar to this

report, we found that overt CD prevalence did not increase
in children with CC; however, our study revealed that CC
is a risk factor for potential CD.
Potential CD is defined as positive celiac serology
with normal villous morphology. Approximately 20%
of the patients with positive serology had normal villous
morphology at the time of initial admission. It was shown
that potential CD is more common in patients with
autoimmune diseases, such as type 1 diabetes mellitus and
autoimmune thyroiditis, and in the first degree relatives
of patients with CD. Additionally, potential CD was also
more common in children who had gluten avoidance, and
in patients who had tTG-IgA positivity, but <100 RU/mL.
The cause of potential CD is unclear, but the lack of innate
immune response or a lower level of proinflammatory
adaptive antigluten immunity may be responsible for
the lack of villous atrophy. Patients with potential CD
were advised to continue their gluten containing diet. In
the follow-up, serology became negative in most of the
patients, but high levels of tTG-IgA may persist in some
patients and villous atrophy and overt CD may develop.
Risk factors for the development of villous atrophy
are male sex, slight mucosal inflammation, presence
or absence of some polymorphisms (AA genotype of
IL12A, AA genotype of RGS1), and presence of intestinal
anti-TG2 IgA deposits (18–20). In our study 75% of the
subjects with potential CD became serologically negative
at the 1 year follow-up under gluten containing diet. Only
25% (3 of the 12 patients) of the patients had persistent
elevated tTG-IgA levels, all had HLA-DQ2 positivity, and
2 had EMA positivity.
Due to the small number of patients with positive
serology, we were not able to analyze the risk factors

tTg-IgA levels
(RU/mL)
patients with
silent CD

>200
200

150

patients with potential
CD in CC group

100

50

0

patients with
potential CD
in healthy
group(red)

at initial examination

6 th month

1 st year

Figure 2. Serological outcome of the subjects with CD (the grey line indicates the normal
upper limit of tTG-IgA).
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for potential CD in children with CC. However, the
presence of malnutrition increases the risk of potential
CD. Additionally, the majority of patients with positive
serology had constipation over 3 years. Although we did
not analyze the quantity of gluten consumption or gluten
avoidance in our study groups, the increased frequency
of potential CD may be associated with gluten avoidance
or low levels of gluten consumption, especially in patients
with CC. It was shown that gluten avoidance is common in
children who had nonspecific gastrointestinal symptoms
(21). Therefore, serum tTG-IgA levels may not increase to

10 times the normal upper limit and total or partial villous
atrophy may not be more prominent. One limitation of
our study is that the dietary gluten consumption of the
participants was not studied with questionnaire forms.
In conclusion, our study revealed that serological
evaluation of CD may be omitted in children with CC at
initial examination. It may be performed in selected cases,
such as in patients with CC associated with prolonged
duration of symptoms or associated with malnutrition. CC
is a risk factor for potential CD, but the majority of patients
became serologically negative on long-term follow-up.
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